If you're wondering whether to buy Viatris (NASDAQ: VTRS) stock this fall, it's important to know the arguments for why it might gain value as well as why it's not the best option.
Generic drug manufacturers can, in theory, be a reliable source of dividend income, not to mention potentially being safer than your average stock thanks to their steady sales of popular medications at low prices. But they can also suffer from slower-than-average growth due to high overhead costs and large debt loads.
Viatris is in the process of demonstrating its merits to investors, and it's approaching a critical period that may see its fortunes improve significantly -- or perhaps struggle to keep up with competitors. So without further ado, let's first learn why the bulls think this stock is going to be a good one to hold over the long term.
Source Fool.com